Main variables;No. of employees;Total
No. of companies carrying out R&D in Biotechnology;Fewer than 250 employees;1.010
No. of companies carrying out R&D in Biotechnology;250 or more employees;69
No. of companies carrying out R&D in Biotechnology;Total;1.078
%Companies according to biotechnology used: Genetic code;Fewer than 250 employees;34
%Companies according to biotechnology used: Genetic code;250 or more employees;49
%Companies according to biotechnology used: Genetic code;Total;35
%Companies according to biotechnology used: Functional units;Fewer than 250 employees;41
%Companies according to biotechnology used: Functional units;250 or more employees;54
%Companies according to biotechnology used: Functional units;Total;42
%Companies according to biotechnology used: Cellular and tissue culturing and engineering;Fewer than 250 employees;25
%Companies according to biotechnology used: Cellular and tissue culturing and engineering;250 or more employees;48
%Companies according to biotechnology used: Cellular and tissue culturing and engineering;Total;27
%Companies according to biotechnology used: Bioprocesses;Fewer than 250 employees;48
%Companies according to biotechnology used: Bioprocesses;250 or more employees;59
%Companies according to biotechnology used: Bioprocesses;Total;49
%Companies according to biotechnology used: Sub-cellular organisms;Fewer than 250 employees;7
%Companies according to biotechnology used: Sub-cellular organisms;250 or more employees;12
%Companies according to biotechnology used: Sub-cellular organisms;Total;8
%Companies according to biotechnology used: Bio-computing;Fewer than 250 employees;22
%Companies according to biotechnology used: Bio-computing;250 or more employees;22
%Companies according to biotechnology used: Bio-computing;Total;22
%Companies according to biotechnology used: Nanobiotechnology;Fewer than 250 employees;14
%Companies according to biotechnology used: Nanobiotechnology;250 or more employees;18
%Companies according to biotechnology used: Nanobiotechnology;Total;14
%Companies according to biotechnology used: Other;Fewer than 250 employees;12
%Companies according to biotechnology used: Other;250 or more employees;8
%Companies according to biotechnology used: Other;Total;12
Companies in which biotechnology activities are: Main and/or exclusive;Fewer than 250 employees;511
Companies in which biotechnology activities are: Main and/or exclusive;250 or more employees;15
Companies in which biotechnology activities are: Main and/or exclusive;Total;526
Companies in which biotechnology activities are: A secondary line of business;Fewer than 250 employees;155
Companies in which biotechnology activities are: A secondary line of business;250 or more employees;18
Companies in which biotechnology activities are: A secondary line of business;Total;173
Companies in which biotechnology activities are: A tool necessary for production;Fewer than 250 employees;344
Companies in which biotechnology activities are: A tool necessary for production;250 or more employees;35
Companies in which biotechnology activities are: A tool necessary for production;Total;379
%Company by field(s) of ultimate application of biotechnology use: Human Health;Fewer than 250 employees;48
%Company by field(s) of ultimate application of biotechnology use: Human Health;250 or more employees;50
%Company by field(s) of ultimate application of biotechnology use: Human Health;Total;48
%Company by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture;Fewer than 250 employees;21
%Company by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture;250 or more employees;5
%Company by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture;Total;20
%Company by field(s) of ultimate application of biotechnology use: Food products;Fewer than 250 employees;32
%Company by field(s) of ultimate application of biotechnology use: Food products;250 or more employees;36
%Company by field(s) of ultimate application of biotechnology use: Food products;Total;33
%Company by field(s) of ultimate application of biotechnology use: Agriculture and forest production;Fewer than 250 employees;24
%Company by field(s) of ultimate application of biotechnology use: Agriculture and forest production;250 or more employees;21
%Company by field(s) of ultimate application of biotechnology use: Agriculture and forest production;Total;24
%Company by field(s) of ultimate application of biotechnology use: Environment;Fewer than 250 employees;15
%Company by field(s) of ultimate application of biotechnology use: Environment;250 or more employees;15
%Company by field(s) of ultimate application of biotechnology use: Environment;Total;15
%Company by field(s) of ultimate application of biotechnology use: Industry;Fewer than 250 employees;14
%Company by field(s) of ultimate application of biotechnology use: Industry;250 or more employees;6
%Company by field(s) of ultimate application of biotechnology use: Industry;Total;14
Personnel in R&D in biotechnology (no. of persons);Fewer than 250 employees;7.849
Personnel in R&D in biotechnology (no. of persons);250 or more employees;2.342
Personnel in R&D in biotechnology (no. of persons);Total;10.191
Personnel in R&D in biotechnology (no. of persons): Researchers;Fewer than 250 employees;4.469
Personnel in R&D in biotechnology (no. of persons): Researchers;250 or more employees;1.305
Personnel in R&D in biotechnology (no. of persons): Researchers;Total;5.774
Personnel in R&D in biotechnology (no. of persons): Technicians and assistants;Fewer than 250 employees;3.380
Personnel in R&D in biotechnology (no. of persons): Technicians and assistants;250 or more employees;1.037
Personnel in R&D in biotechnology (no. of persons): Technicians and assistants;Total;4.417
Personnel in R&D in biotechnology (no. of persons): women;Fewer than 250 employees;4.199
Personnel in R&D in biotechnology (no. of persons): women;250 or more employees;1.326
Personnel in R&D in biotechnology (no. of persons): women;Total;5.525
Personnel in R&D in biotechnology (no. of persons): (women) Researchers;Fewer than 250 employees;2.320
Personnel in R&D in biotechnology (no. of persons): (women) Researchers;250 or more employees;695
Personnel in R&D in biotechnology (no. of persons): (women) Researchers;Total;3.015
Personnel in R&D in biotechnology (no. of persons): (women) Technicians and assistants;Fewer than 250 employees;1.879
Personnel in R&D in biotechnology (no. of persons): (women) Technicians and assistants;250 or more employees;631
Personnel in R&D in biotechnology (no. of persons): (women) Technicians and assistants;Total;2.511
Personnel in R&D in biotechnology (FTE);Fewer than 250 employees;5.530,1
Personnel in R&D in biotechnology (FTE);250 or more employees;1.661,2
Personnel in R&D in biotechnology (FTE);Total;7.191,4
Personnel in R&D in biotechnology (FTE): Researchers;Fewer than 250 employees;3.333
Personnel in R&D in biotechnology (FTE): Researchers;250 or more employees;943,6
Personnel in R&D in biotechnology (FTE): Researchers;Total;4.276,6
Personnel in R&D in biotechnology (FTE): Technicians and assistants;Fewer than 250 employees;2.197,1
Personnel in R&D in biotechnology (FTE): Technicians and assistants;250 or more employees;717,6
Personnel in R&D in biotechnology (FTE): Technicians and assistants;Total;2.914,7
Personnel in R&D in biotechnology (FTE): women;Fewer than 250 employees;3.061
Personnel in R&D in biotechnology (FTE): women;250 or more employees;924,4
Personnel in R&D in biotechnology (FTE): women;Total;3.985,4
Personnel in R&D in biotechnology (FTE): (women) Researchers;Fewer than 250 employees;1.742,1
Personnel in R&D in biotechnology (FTE): (women) Researchers;250 or more employees;491,9
Personnel in R&D in biotechnology (FTE): (women) Researchers;Total;2.234
Personnel in R&D in biotechnology (FTE): (women) Technicians and assistants;Fewer than 250 employees;1.318,9
Personnel in R&D in biotechnology (FTE): (women) Technicians and assistants;250 or more employees;432,5
Personnel in R&D in biotechnology (FTE): (women) Technicians and assistants;Total;1.751,4
Internal expenditure on R&D (thousands of euros);Fewer than 250 employees;441.736
Internal expenditure on R&D (thousands of euros);250 or more employees;136.435
Internal expenditure on R&D (thousands of euros);Total;578.171
1) By nature of the expense: Current expenses;Fewer than 250 employees;387.035
1) By nature of the expense: Current expenses;250 or more employees;130.565
1) By nature of the expense: Current expenses;Total;517.601
1.1) Remuneration to researchers;Fewer than 250 employees;158.420
1.1) Remuneration to researchers;250 or more employees;55.335
1.1) Remuneration to researchers;Total;213.755
1.2) Remuneration to technicians and assistants;Fewer than 250 employees;74.027
1.2) Remuneration to technicians and assistants;250 or more employees;24.413
1.2) Remuneration to technicians and assistants;Total;98.440
1.3) Other current expenses;Fewer than 250 employees;154.588
1.3) Other current expenses;250 or more employees;50.818
1.3) Other current expenses;Total;205.406
2) By nature of the expense: Capital expenses;Fewer than 250 employees;54.701
2) By nature of the expense: Capital expenses;250 or more employees;5.870
2) By nature of the expense: Capital expenses;Total;60.570
2.1) Land and buildings;Fewer than 250 employees;22.554
2.1) Land and buildings;250 or more employees;54
2.1) Land and buildings;Total;22.609
2.2) Equipment and instruments;Fewer than 250 employees;30.685
2.2) Equipment and instruments;250 or more employees;5.483
2.2) Equipment and instruments;Total;36.169
2.3) Acquisition of specific R&D software;Fewer than 250 employees;1.461
2.3) Acquisition of specific R&D software;250 or more employees;332
2.3) Acquisition of specific R&D software;Total;1.793
1) By origin of the funds: National funds;Fewer than 250 employees;379.550
1) By origin of the funds: National funds;250 or more employees;108.064
1) By origin of the funds: National funds;Total;487.615
1.1) Own funds;Fewer than 250 employees;249.390
1.1) Own funds;250 or more employees;81.068
1.1) Own funds;Total;330.459
1.2) From companies;Fewer than 250 employees;32.831
1.2) From companies;250 or more employees;12.630
1.2) From companies;Total;45.462
1.3) Public Administration funds;Fewer than 250 employees;53.162
1.3) Public Administration funds;250 or more employees;13.028
1.3) Public Administration funds;Total;66.189
1.4) From Universities;Fewer than 250 employees;25.148
1.4) From Universities;250 or more employees;.
1.4) From Universities;Total;25.148
1.5) From non profit private institutions;Fewer than 250 employees;19.019
1.5) From non profit private institutions;250 or more employees;1.338
1.5) From non profit private institutions;Total;20.357
1) By origin of the funds: Foreign funds;Fewer than 250 employees;62.186
1) By origin of the funds: Foreign funds;250 or more employees;28.371
1) By origin of the funds: Foreign funds;Total;90.556
2.1) From EU programmes;Fewer than 250 employees;18.782
2.1) From EU programmes;250 or more employees;2.150
2.1) From EU programmes;Total;20.932
2.2) Other foreign funds;Fewer than 250 employees;43.403
2.2) Other foreign funds;250 or more employees;26.221
2.2) Other foreign funds;Total;69.624
Purchase of R&D services in biotechnology (thousands of euros);Fewer than 250 employees;111.514
Purchase of R&D services in biotechnology (thousands of euros);250 or more employees;54.508
Purchase of R&D services in biotechnology (thousands of euros);Total;166.022
Purchase of R&D services in biotechnology (thousands of euros): In Spain;Fewer than 250 employees;67.448
Purchase of R&D services in biotechnology (thousands of euros): In Spain;250 or more employees;30.007
Purchase of R&D services in biotechnology (thousands of euros): In Spain;Total;97.455
Purchase of R&D services in biotechnology (thousands of euros): Abroad;Fewer than 250 employees;44.065
Purchase of R&D services in biotechnology (thousands of euros): Abroad;250 or more employees;24.501
Purchase of R&D services in biotechnology (thousands of euros): Abroad;Total;68.567
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital;Fewer than 250 employees;47
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital;250 or more employees;30
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital;Total;46
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information;Fewer than 250 employees;13
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information;250 or more employees;12
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information;Total;13
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources;Fewer than 250 employees;14
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources;250 or more employees;16
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources;Total;14
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain;Fewer than 250 employees;14
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain;250 or more employees;13
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain;Total;14
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of access to international markets;Fewer than 250 employees;18
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of access to international markets;250 or more employees;14
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of access to international markets;Total;17
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of distribution and sales channels;Fewer than 250 employees;17
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of distribution and sales channels;250 or more employees;12
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of distribution and sales channels;Total;17
%Companies that consider the following obstacles as very important considering biotechnology development: Acceptance / public perception;Fewer than 250 employees;18
%Companies that consider the following obstacles as very important considering biotechnology development: Acceptance / public perception;250 or more employees;17
%Companies that consider the following obstacles as very important considering biotechnology development: Acceptance / public perception;Total;18
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements;Fewer than 250 employees;35
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements;250 or more employees;36
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements;Total;35
%Companies that consider the following obstacles as very important considering biotechnology development: Time / cost;Fewer than 250 employees;50
%Companies that consider the following obstacles as very important considering biotechnology development: Time / cost;250 or more employees;34
%Companies that consider the following obstacles as very important considering biotechnology development: Time / cost;Total;49
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting;Fewer than 250 employees;22
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting;250 or more employees;9
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting;Total;21
% Companies that have requested biotechnology patents in Biotechnology;Fewer than 250 employees;15
% Companies that have requested biotechnology patents in Biotechnology;250 or more employees;21
% Companies that have requested biotechnology patents in Biotechnology;Total;15
Number of patents requested;Fewer than 250 employees;451
Number of patents requested;250 or more employees;75
Number of patents requested;Total;526
% Companies with income of an international origin related to biotechnological activities;Fewer than 250 employees;26,4
% Companies with income of an international origin related to biotechnological activities;250 or more employees;19,1
% Companies with income of an international origin related to biotechnological activities;Total;26
% Turnover representing income of an international origin related to biotechnological activities;Fewer than 250 employees;6,5
% Turnover representing income of an international origin related to biotechnological activities;250 or more employees;0,8
% Turnover representing income of an international origin related to biotechnological activities;Total;1,4
% Income of an international origin related to biotechnological activities distributed in: Income received from the EU;Fewer than 250 employees;51,6
% Income of an international origin related to biotechnological activities distributed in: Income received from the EU;250 or more employees;76,3
% Income of an international origin related to biotechnological activities distributed in: Income received from the EU;Total;63,8
% Income of an international origin related to biotechnological activities distributed in: Income received from other countries;Fewer than 250 employees;48,4
% Income of an international origin related to biotechnological activities distributed in: Income received from other countries;250 or more employees;23,7
% Income of an international origin related to biotechnological activities distributed in: Income received from other countries;Total;36,2
% Income of an international origin related to biotechnological activities by classification: Internacional trade in products and services;Fewer than 250 employees;85,6
% Income of an international origin related to biotechnological activities by classification: Internacional trade in products and services;250 or more employees;97,7
% Income of an international origin related to biotechnological activities by classification: Internacional trade in products and services;Total;91,6
% Income of an international origin related to biotechnological activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;Fewer than 250 employees;1,4
% Income of an international origin related to biotechnological activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;250 or more employees;0,5
% Income of an international origin related to biotechnological activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;Total;0,9
% Income of an international origin related with activities according to the classification: Operating source abroad;Fewer than 250 employees;3
% Income of an international origin related with activities according to the classification: Operating source abroad;250 or more employees;0,7
% Income of an international origin related with activities according to the classification: Operating source abroad;Total;1,9
% Income of an international origin related with activities according to the classification: Other;Fewer than 250 employees;10,1
% Income of an international origin related with activities according to the classification: Other;250 or more employees;1,1
% Income of an international origin related with activities according to the classification: Other;Total;5,6